广誉远龟龄集品牌怎么样 申请店铺

我要投票 广誉远龟龄集在保健酒行业中的票数:351 更新时间:2025-05-26
广誉远龟龄集是哪个国家的品牌?「广誉远龟龄集」是 山西广誉远国药有限公司 旗下著名品牌。该品牌发源于山西,由创始人张斌在1998-02-25期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力广誉远龟龄集品牌出海!将品牌入驻外推网,定制广誉远龟龄集品牌推广信息,可以显著提高广誉远龟龄集产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

广誉远龟龄集怎么样

广誉远始创于明嘉靖二十年(公元1541年),距今已有473年的历史,其间历经广盛号药店、广升聚、广升蔚、广升誉、广升远、山西中药厂、山西广誉远等十几个商号药厂更迭。在清代曾与广州陈李济(1600年创建)、北京同仁堂(1669年创建)、杭州胡庆余堂(1874年创建)并称为“四大药店”,现为山西省中药企业典范,并在2006年成为首批被中华人民共和国商务部认定的“中华老字号”企业。

广誉远主导产品“龟龄集”和“定坤丹”,是中华中医药宝库珍藏的养生至宝,是博大精深的中医药文化的智慧结晶,现为国家级保密处方,分别在2008年和2011年被中华人民共和国国务院评为国家级非物质文化遗产。龟龄集、定坤丹,“御用圣品”的宫廷出身,数百年的药用历史,深刻佐证了其功效卓著;多位皇帝的相关御批,真实确凿的史料档案,更显其品味尊贵。包括龟龄集、定坤丹在内,广誉远系列产品荣获众多国际级奖项、国家级荣誉,在国际传统医药界有深远影响。

广誉远拥有丰富的产品服务群,有丸剂、胶囊剂、酒剂、片剂、颗粒剂、散剂、口服液、煎膏剂共八个剂型,继承着龟龄集、定坤丹、安宫牛黄丸、牛黄清心丸、六味地黄丸、乌鸡白凤丸等103种中药古方及炮制工艺,从方剂、配伍、选材、炮制等诸多方面,承载并展现着中华中医药文化的核心精神与巨大价值。

“尊德贵生,传承创新”是广誉远的企业理念,广誉远坚定地以文化为先导,专注于中医药领域,坚持“继承与创新”的发展策略,充分利用企业内部的产品资源,通过持续的品牌建设和创新营销,走出“特色”道路,努力打造“人无我有,人有我优,做中国最具特色的国药”之企业形象,并在未来五年内,推出精品中药“百家千店”工程,在全国范围内建立100家国医馆、1000家国药堂,包括人参、鹿茸、枸杞、西红花、地黄、肉苁蓉、参等九大GAP养植基地。

473年来,广誉远严苛制药,精益求精,秉承“修合虽无人见,存心自有天知”的古训,遵循“非义而为,一介不取;合情之道,九百何辞”的准则,恪守诚信自律的晋商精神,以信誉为根本,“以义制利”铸就了百年老店的历久弥新。

2003年,由全国著名的大型现代化医药企业——西安东盛集团投资控股,结合现代管理运营理念,将广誉远传统老店,发展成为集中成药研发、生产、销售于一体的高科技现代化制药企业。在国家“十二五规划”对中医药行业的明确指导下,在祖国全面建设小康社会的新时期,在中华民族伟大复兴的历史时刻,广誉远以精品养生中药回馈社会大众,开创智慧养生的新纪元。广誉远作为中国非物质文化遗产的传承者,将为振兴传统中医药文化,贡献应尽的社会责任与历史使命,树立起中医药文化的全新价值。

Guangyuyuan was founded in the 20th year of Jiajing, Ming Dynasty (1541 A.D.), which has a history of 473 years. During this period, guangyuyuan has experienced the change of more than ten famous pharmaceutical companies, such as Guangsheng drugstore, guangshengju, guangshengwei, guangshengyu, guangshengyuan, Shanxi Traditional Chinese medicine factory and Shanxi guangyuyuan. In the Qing Dynasty, it was named as "four drugstores" together with Chen Liji in Guangzhou (founded in 1600), Tongrentang in Beijing (founded in 1669) and Hu qingyutang in Hangzhou (founded in 1874). It is now a model of traditional Chinese medicine enterprises in Shanxi Province, and became one of the first batch of "old Chinese brand" enterprises recognized by the Ministry of Commerce of the people's Republic of China in 2006. Guangyuyuan's leading products "Guilingji" and "dingkundan" are the treasure of health preservation in the treasure house of traditional Chinese medicine, and the wisdom crystallization of extensive and profound traditional Chinese medicine culture. They are now state-level secret prescriptions, and were rated as national intangible cultural heritage by the State Council of the people's Republic of China in 2008 and 2011 respectively. Guilingji, dingkundan, the Royal origin of "imperial holy product", and hundreds of years of medicinal history, have proved its remarkable efficacy; the relevant imperial approvals of several emperors, authentic historical data files, show its taste and dignity. Including Guilingji and dingkundan, guangyuyuan series products have won many international and national awards, and have a profound influence in the international traditional medicine industry. Guangyuyuan has a wealth of product service groups, including eight dosage forms of pills, capsules, liquors, tablets, granules, powders, oral liquids and decoctions. It inherits 103 traditional Chinese medicine prescriptions and processing technologies, including Guilingji, dingkundan, Angongniuhuang, Niuhuang Qingxin, Liuwei Dihuang, Wuji Baifeng, etc., and carries and manufactures from many aspects, such as prescriptions, compatibility, material selection and processing It shows the core spirit and great value of Chinese traditional medicine culture. "Respecting morality, valuing health, inheriting innovation" is guangyuyuan ' In the next five years, we will launch the project of "one hundred thousand stores" of high-quality traditional Chinese medicine, and set up 100 national medicine halls and 1000 national medicine halls nationwide, including nine GAP cultivation bases including ginseng, antler, Lycium, crocus, rehmannia, Cistanche deserticola and ginseng. In the past 473 years, guangyuyuan has been strict in pharmaceutical industry, striving for perfection, adhering to the ancient motto of "no one can see the mending, no one can take it; the way to be reasonable, nine hundred words", abiding by the spirit of integrity and self-discipline of Shanxi merchants, taking reputation as the foundation, and "making profits by righteousness" has made the century old shop new for a long time. In 2003, Xi'an Dongsheng Group, a famous modern pharmaceutical enterprise in China, invested and held the shares, combined with the modern management and operation concept, and developed guangyuyuan traditional old store into a high-tech modern pharmaceutical enterprise integrating the research and development, production and sales of patent medicine. Under the clear guidance of the 12th Five Year Plan for the industry of traditional Chinese medicine, in the new era of building a well-off society in an all-round way in the motherland, and at the historical moment of the great rejuvenation of the Chinese nation, it is well-known for giving back to the public with high-quality health care traditional Chinese medicine and creating a new era of intelligent health care. Guangyuyuan, as the inheritor of Chinese intangible cultural heritage, will contribute to the revitalization of traditional Chinese medicine culture, social responsibility and historical mission, and establish a new value of Chinese medicine culture.

本文链接: https://brand.waitui.com/90f4e668b.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

科源制药:持股5%以上股东问泽鸿拟减持不超3%公司股份

科源制药5月25日公告,公司持股5%以上股东问泽鸿计划自减持计划公告之日起15个交易日后的3个月内,通过集中竞价及大宗交易方式减持公司股份不超过324.87万股,即不超过公司总股本的3%。其中,通过集中竞价交易方式减持不超过108.29万股,通过大宗交易方式减持不超过216.58万股。减持价格将根据市场价格确定,且不低于发行价。减持原因为自身资金需要。

49分钟前

中信证券:核心资产定价权逐步向南转移

中信证券研报表示,本轮A股公司密集赴港IPO是出海战略、制度便利和港股流动性改善三重力量助推。优质核心资产在港股正式交易后,短期会活跃对应A股的交易,部分核心资产的定价权可能会逐步南移。这个现象的背后是港股市场的吸引力在系统性提升,一是资产供给结构和质量在持续提高,二是流动性在海外资金回流的背景下趋势性改善,从历史上看,港交所每一轮制度的改革突破都带来了顺应时代特征的牛市。未来,更多优质龙头赴港上市可能成为A股市场风格重新转向核心资产的催化剂。

49分钟前

巴基斯坦为比特币挖矿分配2000兆瓦电力装机容量

巴基斯坦在全国范围内支持比特币挖矿和人工智能数据中心的第一阶段计划中,已分配2000兆瓦电力装机容量。目前该国正推动加密货币合法化并吸引外国投资。巴基斯坦财政部在一份声明中表示,这项由巴基斯坦加密货币委员会主导的计划,还将有助于实现剩余能源的货币化并创造高科技就业岗位。财政部称,萨希瓦尔(Sahiwal)、中国枢纽(China Hub)和卡西姆港(Port Qasim)等目前以15%产能运行的燃煤发电项目,预计将被改用于这一计划。(财联社)

49分钟前

众生药业:子公司一类创新药RAY1225注射液两项降糖III期临床试验获伦理批件

5月25日,众生药业公告称,公司控股子公司广东众生睿创生物科技有限公司自主研发的一类创新多肽药物RAY1225注射液用于2型糖尿病(T2DM)患者的两项III期临床试验(SHINING-2和SHINING-3)获得组长单位北京大学人民医院伦理审查批件,批准项目开展。RAY1225注射液是具有全球自主知识产权的创新结构多肽药物,具有GLP-1受体和GIP受体双重激动活性。

49分钟前

存款利率跌破“1”时代,储户转战“新三金”配置

5月下旬,六大国有银行集体下调利率,一年期定存首次跌破1%,活期利率仅0.05%。近一周以来,十余家中小银行紧随大行降息步伐,将最高定存利率压至1.7%以下。部分银行同步调低大额存单利率,并下架2年期以上产品。目前大行大额存单利率多未超过1.4%。部分民营银行调降后,可购大额存单最高利率也仅为1.65%。面对低利率时代,年轻人开始寻找“存款替代”,“货币基金+债基+黄金”的“新三金”配置成为新宠。蚂蚁财富公布的数据显示,截至2025年4月底,有937万90后、00后同时配置了余额宝货币基金、债券基金、黄金基金,“新三金”浪潮持续发酵。(第一财经)

49分钟前

本页详细列出关于广誉远龟龄集的品牌信息,含品牌所属公司介绍,广誉远龟龄集所处行业的品牌地位及优势。
咨询